Medication info
Fosamax Plus D Tablet

Fosamax Plus D Tablet

Prescription medicationTabletOral
Ingredient · strength
Sodium Alendronate Hydrate›91.37mg / 1 tabletCholecalciferol Concentrate Granules›53.33mg / 1 tablet
Manufacturer / importer
Organon Korea Co., Ltd.
Appearance
White to grayish-white rectangular tablets, one side is engraved with 270, and the other side has a bone image.
Packaging
4 tablets/PTP
Approval status
Active

MFDS item code 200711426 · Approved 2007.10.18 · Insurance code 073100280

Summary

Main use
Treatment of osteoporosis in postmenopausal women and men
Who takes it
Adults · Children
Adult dose
Take 1 tablet of this drug once weekly (70 mg/2800 IU or 70 mg/5600 IU) in the morning with a sufficient amount of water, at least 30 minutes before consuming food, beverages, or other medicines (see “General Precautions”). The appropriate dose for most patients with osteoporosis is 70 mg/5600 IU once weekly. The appropriate duration of treatment has not been established. The safety and efficacy of this drug for the treatment of osteoporosis are based on 4 years of clinical data. The need for continued treatment should be regularly reassessed in all patients receiving bisphosphonates. In patients at low risk of fracture, discontinuation should be considered after 3~5 years of treatment. The risk of fracture should be regularly reassessed in patients who discontinue treatment. Other beverages or food, including mineral water and barley tea, and medicines may reduce the absorption of alendronate (see “Interactions”). Consuming food within 30 minutes after taking this drug or at the same time may reduce the absorption of alendronate and decrease its effect. This drug should be taken immediately after getting up in the morning and swallowed with a sufficient amount of water (170∼230 mL) to facilitate rapid delivery of the medicine to the stomach and reduce the possibility of esophageal irritation. Do not lie down for at least 30 minutes after taking the drug and until after the first food intake. Do not take this drug at bedtime or before getting up. Failure to follow these instructions may increase the risk of esophageal adverse reactions (see “Warnings” and “General Precautions”). Patients whose dietary intake of calcium and vitamin D is insufficient should take supplements (see Precautions for Use, 4. General Precautions, 2) Information to Be Provided to Patients (4)). Patients at high risk of vitamin D deficiency (e.g., patients over 70 years of age, patients in nursing homes, patients with chronic diseases) may require additional vitamin D supplements. Patients with gastrointestinal malabsorption syndrome may require higher doses of vitamin D supplements, and measurement of 25-hydroxyvitamin D levels should be considered. The recommended daily intake of vitamin D is 400 IU to 800 IU. Taking this drug once weekly provides a week's supply of 400 IU and 800 IU of vitamin D per day. If a patient taking 1 tablet of this drug forgets to take it on the scheduled day, take 1 tablet the next morning, resume taking it on the originally scheduled day, and continue taking it regularly once weekly thereafter. Do not take 2 tablets on the same day. Administration to older adults (65 years of age and older): No dose adjustment is necessary. Administration to patients with renal impairment: No dose adjustment is necessary for patients with mild to moderate renal impairment (creatinine clearance 35∼60 mL/min); however, administration of this drug is not recommended for patients with severe renal impairment (creatinine clearance less than 35 mL/min), because clinical experience is insufficient.
Child dose
Children and adolescents (under 18 years of age): The safety and efficacy in children and adolescents have not been established.

Ingredients

Importer
Organon Korea Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women and men

  • Osteoporosis
View approved original text

This medication is used for the treatment of osteoporosis in postmenopausal women and men.

How to take

Adult dose

Take 1 tablet of this drug once weekly (70 mg/2800 IU or 70 mg/5600 IU) in the morning with a sufficient amount of water, at least 30 minutes before consuming food, beverages, or other medicines (see “General Precautions”). The appropriate dose for most patients with osteoporosis is 70 mg/5600 IU once weekly. The appropriate duration of treatment has not been established. The safety and efficacy of this drug for the treatment of osteoporosis are based on 4 years of clinical data. The need for continued treatment should be regularly reassessed in all patients receiving bisphosphonates. In patients at low risk of fracture, discontinuation should be considered after 3~5 years of treatment. The risk of fracture should be regularly reassessed in patients who discontinue treatment. Other beverages or food, including mineral water and barley tea, and medicines may reduce the absorption of alendronate (see “Interactions”). Consuming food within 30 minutes after taking this drug or at the same time may reduce the absorption of alendronate and decrease its effect. This drug should be taken immediately after getting up in the morning and swallowed with a sufficient amount of water (170∼230 mL) to facilitate rapid delivery of the medicine to the stomach and reduce the possibility of esophageal irritation. Do not lie down for at least 30 minutes after taking the drug and until after the first food intake. Do not take this drug at bedtime or before getting up. Failure to follow these instructions may increase the risk of esophageal adverse reactions (see “Warnings” and “General Precautions”). Patients whose dietary intake of calcium and vitamin D is insufficient should take supplements (see Precautions for Use, 4. General Precautions, 2) Information to Be Provided to Patients (4)). Patients at high risk of vitamin D deficiency (e.g., patients over 70 years of age, patients in nursing homes, patients with chronic diseases) may require additional vitamin D supplements. Patients with gastrointestinal malabsorption syndrome may require higher doses of vitamin D supplements, and measurement of 25-hydroxyvitamin D levels should be considered. The recommended daily intake of vitamin D is 400 IU to 800 IU. Taking this drug once weekly provides a week's supply of 400 IU and 800 IU of vitamin D per day. If a patient taking 1 tablet of this drug forgets to take it on the scheduled day, take 1 tablet the next morning, resume taking it on the originally scheduled day, and continue taking it regularly once weekly thereafter. Do not take 2 tablets on the same day. Administration to older adults (65 years of age and older): No dose adjustment is necessary. Administration to patients with renal impairment: No dose adjustment is necessary for patients with mild to moderate renal impairment (creatinine clearance 35∼60 mL/min); however, administration of this drug is not recommended for patients with severe renal impairment (creatinine clearance less than 35 mL/min), because clinical experience is insufficient.

Child dose

Children and adolescents (under 18 years of age): The safety and efficacy in children and adolescents have not been established.

Precautions

This drug can irritate the upper gastrointestinal tract mucosa, leading to adverse reactions such as esophagitis, esophageal ulcers, and esophageal erosion. If symptoms such as dysphagia, odynophagia, retrosternal pain, or heartburn occur, stop taking immediately and consult a doctor. Take this medication with a sufficient amount of water and do not lie down for at least 30 minutes after taking it. The alendronate ingredient should not be administered to patients with esophageal motility disorders, those who cannot remain upright for 30 minutes, patients with hypersensitivity to the ingredient, patients with hypocalcemia, and those who are lactose intolerant. This medication is used for osteoporosis treatment and has reported adverse reactions such as musculoskeletal pain, gastrointestinal symptoms (abdominal pain, nausea, dyspepsia, etc.), headaches, dizziness, rashes, etc. Special caution is advised for those with a history of gastrointestinal diseases or in combination with non-steroidal anti-inflammatory drugs as gastrointestinal irritation may increase. This drug should be used with caution during pregnancy and breastfeeding. It is not recommended for use in children, and elderly patients can use it without special dosage adjustments but may require vitamin D supplementation. It is not recommended for patients with severely impaired renal function. When taking, there should be at least a 30-minute interval from other calcium supplements or antacids, and instructions for usage and precautions must be fully understood and followed. In the case of overdose, gastrointestinal irritation and symptoms of hypocalcemia may occur, so consult a medical professional immediately. This medication should be stored out of reach of children and should not be transferred to another container.

Side effects

esophagitis, esophageal ulcer, esophageal erosion, esophageal obstruction, esophageal perforation, bleeding, dysphagia, odynophagia, retrosternal pain, heartburn, abdominal pain, nausea, indigestion, constipation, diarrhea, flatulence, acid reflux, vomiting, abdominal distension, gastritis, musculoskeletal (bone, muscle, or joint) pain, muscle cramps, headache, dizziness, dysgeusia, rash, erythema, anastomotic ulcer, esophageal stricture, oropharyngeal ulcer, gastric ulcer, duodenal ulcer, hypocalcemia, peripheral edema, urticaria, angioedema, myalgia, fatigue, asthenia, fever, localized osteonecrosis of the jaw, joint swelling, low-energy fractures of the femoral body and other bones, Stevens-Johnson syndrome, toxic epidermal necrolysis, uveitis, scleritis, episcleritis, cholesteatoma of the external auditory canal, rhinitis, hair loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly closed container to protect it from air and moisture. Additionally, it should be stored at room temperature between 1 to 30 degrees Celsius, preferably kept in a dark place to avoid direct light.

Appearance and packaging

Appearance

White to grayish-white rectangular tablets, one side is engraved with 270, and the other side has a bone image.

Package unit

4 tablets/PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.